Ornithine Transcarbamylase Deficiency Clinical Trial
Official title:
A Phase 1b Randomized, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Doses of ARCT-810 in Clinically Stable Patients With Ornithine Transcarbamylase Deficiency
Verified date | April 2023 |
Source | Arcturus Therapeutics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Determine the safety, tolerability and pharmacokinetics of single doses of ARCT-810 in clinically stable patients (stable on standard of care treatment, e.g. diet ± ammonia scavengers) with ornithine transcarbamylase deficiency (OTCD).
Status | Active, not recruiting |
Enrollment | 12 |
Est. completion date | August 2023 |
Est. primary completion date | August 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Adequate cognitive ability to consent and recall symptoms over a 1-week time period 2. Males and females =18 years of age with documented diagnosis of ornithine transcarbamylase deficiency (OTCD) confirmed with genetic testing, or willing to consent to OTC gene sequencing and deletion/duplication testing 3. Subject's ornithine transcarbamylase deficiency (OTCD) is stable as evidenced by 1. no clinical symptoms of hyperammonemia AND b, 2. an ammonia level <100 µmol/L (170 µg/dL) at the screening evaluation Subjects must remain free from symptoms of hyperammonemia throughout the screening period. 4. If using nitrogen ammonia scavenger therapy, must be on a stable regimen (no change in dose or frequency) for = 28 days prior to providing informed consent and throughout the screening period 5. Must have maintained a stable protein-restricted diet (+/- amino acid supplementation) for at least 28 days prior to providing informed consent and continue to maintain a stable diet for the duration of the study 6. Good general health other than OTCD, in the opinion of the Investigator 7. Willing to refrain from strenuous exercise/activity and alcohol for 72 hours before study visits 8. Willingness to comply with procedures and visits 9. Willingness to follow contraception guidelines Exclusion Criteria: 1. History of clinically significant disease(s), in the opinion of the Investigator 2. Clinically significant screening laboratory values 3. Uncontrolled diabetes 4. Clinically significant anemia 5. Subjects who develop infection during screening must be asymptomatic for at least 7 days prior to dosing 6. Unwillingness to comply with study requirements 7. History of positive HIV, hepatitis C, or chronic hepatitis B 8. Uncontrolled hypertension 9. Malignancy within 5 years prior to study 10. Treatment with another investigational drug, biological agent, or device within 30 days of screening, or 5 half-lives of investigational drug 11. Treatment with any oligonucleotide or mRNA within 6 months of screening, with exceptions for some vaccinations and investigational treatments 12. History of gene therapy, hepatocyte or mesenchymal stem cell transplantation 13. Prior organ transplant 14. History of severe allergic reaction to a liposomal product 15. Recent history of, or current, drug or alcohol abuse 16. Dependence on inhaled (smoked or vaped) or oral cannabis products 17. Systemic corticosteroids within 6 weeks prior to screening 18. Blood donation of 50 to 499 mL within 30 days of screening or of .499 mL within 60 days of screening 19. Other conditions, in the opinion of the Investigator, that would make the subject unsuitable for participation |
Country | Name | City | State |
---|---|---|---|
United States | University of Texas Southwestern Medical Center at Dallas | Dallas | Texas |
United States | University of Florida | Gainesville | Florida |
United States | Children's Wisconsin - Milwaukee Hospital | Milwaukee | Wisconsin |
United States | M Health Fairview Masonic Children's Hospital | Minneapolis | Minnesota |
United States | The Mount Sinai Hospital | New York | New York |
United States | Children's Hospital of Pittsburgh | Pittsburgh | Pennsylvania |
United States | University of Utah | Salt Lake City | Utah |
United States | Baylor University | Waco | Texas |
Lead Sponsor | Collaborator |
---|---|
Arcturus Therapeutics, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence, severity and dose-relationship of adverse events (AEs) | Safety and tolerability of ARCT-810 assessed by determining the incidence, severity and dose-relationship of AEs by dose | 4 weeks | |
Secondary | Change in area under the curve after single dose of ARCT-810 | Area under the plasma concentration versus time curve (AUC) from time zero to the last quantifiable time point | Up to 4 weeks | |
Secondary | Maximum observed plasma concentration (Cmax) after single dose of ARCT-810 | The maximum observed plasma concentration (Cmax) | Up to 4 weeks | |
Secondary | Time at which Cmax occurred after single dose of ARCT-810 | The time at which Cmax occurred (Tmax) | Up to 4 weeks | |
Secondary | AUC0-inf after single dose of ARCT-810 | AUC from time zero extrapolated to infinity | Up to 4 weeks | |
Secondary | AUCExtrap after single dose of ARCT-810 | The relative portion of AUC0-inf extrapolated beyond AUC0-t | Up to 4 weeks | |
Secondary | T1/2 after single dose of ARCT-810 | Terminal half-life | Up to 4 weeks | |
Secondary | MRT0-inf after single dose of ARCT-810 | The mean residence time extrapolated to infinity | Up to 4 weeks | |
Secondary | CL after single dose of ARCT-810 | Total body clearance, calculated as dose divided by AUC0-inf | Up to 4 weeks | |
Secondary | Vss after single dose of ARCT-810 | Volume of distribution | Up to 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01569568 -
Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI
|
||
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Terminated |
NCT04717453 -
Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency
|
||
Recruiting |
NCT05910151 -
Selective Screening of Children for Hereditary Metabolic Diseases by Tandem Mass Spectrometry in Kazakhstan
|
||
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Recruiting |
NCT04612764 -
Liver Disease in Urea Cycle Disorders
|
||
Not yet recruiting |
NCT02670889 -
Urease Inhibitor Drug Treatment for Urea Cycle Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT05092685 -
Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEn
|
Phase 1/Phase 2 | |
Completed |
NCT00472732 -
Neurologic Injuries in Adults With Urea Cycle Disorders
|
N/A | |
Terminated |
NCT04909346 -
Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease
|
||
Completed |
NCT04416126 -
Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects
|
Phase 1 | |
Recruiting |
NCT05526066 -
Study for Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810
|
Phase 2 | |
Completed |
NCT00718627 -
Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders
|
Phase 2 | |
Recruiting |
NCT04908319 -
Hepatic Histopathology in Urea Cycle Disorders
|
||
Withdrawn |
NCT03767270 -
Safety, Tolerability and PK/PD Evaluation of Intravenous Administration of MRT5201 in Patients With OTC Deficiency
|
Phase 1/Phase 2 | |
Completed |
NCT04269122 -
A Study to Assess Plasma Ammonia Time-Normalized Area Under the Curve and Rate of Ureagenesis in Healthy Adult Subjects
|
||
Recruiting |
NCT06255782 -
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency (OTC-HOPE)
|
Phase 1/Phase 2 |